Relmada Therapeutics Inc (RLMD)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

880 3RD AVENUE, 12TH FLOOR NEW YORK, NY 10022

Relmada Therapeutics, Inc. is a clinical-stage pharmaceutical company developing novel therapies for the treatment of chronic pain.

Data as of 2020-09-12
Market Cap580.708 Million Shares Outstanding16.024 Million Avg 30-day Volume73.026 Thousand
P/E Ratio Dividend Yield EPS-2.22
Price/Sales Price cash flow ratio Price free cash flow ratio-39.8
Book Value8.25 Price to Tangible Book4.46 Alpha0.04
Short Interest Ratio % Short Interest to Float R-squared0.002132
BETA0.345103 52-week High/Low54.0 / 9.6 Stddev0.319325
View SEC Filings from RLMD instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 4 3 33.33% 1 (0.07%) 0 (0.0%)
Funds Holding: 75 44 70.45% 21 (1.37%) 13 (0.83%) 61.54%
13F shares: 10.506 Million 9.357 Million 12.28% 5.008 Million 4.467 Million 12.1%
% Ownership 69.1284 62.6322 10.37% 32.9512 29.9026 10.2%
New Positions: 40 12 233.33% 12 4 200.0%
Increased Positions 20 18 11.11% 5 7 -28.57%
Closed Positions 8 12 -33.33% 4 5 -20.0%
Reduced Positions 7 7 0.0% 3 1 200.0%
Total Calls 254.639 Thousand 27.806 Thousand 815.77% 94.3 Thousand
Total Puts 12.4 Thousand 100 12300.0%
PUT/CALL Ratio 0.05 0.0 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding RLMD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RLMD BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

6 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

98.4 Thousand total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CASAMENTO CHARLES J

  • Director
76,657 2020-09-01 7

TRAVERSA SERGIO CEO

  • Officer
  • Director
75,493 2020-08-18 2

KELLY PAUL EDWARD

  • Director
147,295 2020-08-18 3

SCHMIDT ERIC THOMAS

  • Director
100,000 2020-04-09 2

WESSEL THOMAS EVP, HEAD OF R&D

  • Officer
0 2020-03-09 1

SHENOUDA MAGED

  • Director
0 2019-12-19 2

VITOLO OTTAVIO V. CMO

  • Officer
0 2019-12-19 1

ENCE CHUCK CFO

  • Officer
0 2019-12-19 1

GLASSPOOL JOHN

  • Director
0 2019-12-19 2

AGHARKAR SHREERAM

  • Director
5,759 2015-12-31 0

SETH SANDESH

  • Director
123,258 2015-12-15 0

NOLAN LISA CHIEF BUSINESS OFFICER

  • Officer
10,000 2015-12-14 0

BECK DOUGLAS CHIEF FINANCIAL OFFICER

  • Officer
0 2015-02-23 0

SALINAS ELISEO ORESTE PRESIDENT AND CSO

  • Officer
0 2015-02-23 0

YAZGI NABIL

  • Director
185,000 2015-01-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

CASAMENTO CHARLES J - Director

2020-09-02 16:36:41 -0400 2020-09-01 S 3,000 $34.74 d 55,173 direct 0.2185 -1.0377 1.9115 4 -1.0377 6

CASAMENTO CHARLES J - Director

2020-08-19 16:13:23 -0400 2020-08-18 F 2,189 $39.03 d 58,173 direct -3.0762 -14.6118 0.0 1 -14.6118 6

TRAVERSA SERGIO - Director - Officer CEO

2020-08-19 16:15:06 -0400 2020-08-18 F 4,151 $39.03 d 75,493 direct -3.0762 -14.6118 0.0 1 -14.6118 6

KELLY PAUL EDWARD - Director

2020-08-19 16:16:39 -0400 2020-08-18 F 1,826 $39.03 d 147,295 direct -3.0762 -14.6118 0.0 1 -14.6118 6

CASAMENTO CHARLES J - Director

2020-08-19 16:13:23 -0400 2020-08-18 M 26,362 $3.24 a 60,362 direct -3.0762 -14.6118 0.0 1 -14.6118 6

TRAVERSA SERGIO - Director - Officer CEO

2020-08-19 16:15:06 -0400 2020-08-18 M 50,008 $3.24 a 79,644 direct -3.0762 -14.6118 0.0 1 -14.6118 6

KELLY PAUL EDWARD - Director

2020-08-19 16:16:39 -0400 2020-08-18 M 22,000 $3.24 a 149,121 direct -3.0762 -14.6118 0.0 1 -14.6118 6

CASAMENTO CHARLES J - Director

2020-08-19 16:13:23 -0400 2020-08-18 M 26,362 d 33,404 direct

TRAVERSA SERGIO - Director - Officer CEO

2020-08-19 16:15:06 -0400 2020-08-18 M 50,008 d 162,492 direct

KELLY PAUL EDWARD - Director

2020-08-19 16:16:39 -0400 2020-08-18 M 22,000 d 90,500 direct

CASAMENTO CHARLES J - Director

2020-08-04 15:30:48 -0400 2020-08-03 S 3,000 $35.74 d 34,000 direct -4.6475 -1.6108 2.9575 6.4431 12 -9.1101 17

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments